
Bernhard Schwarz,1 Laia Solé-Feu,2 Yannick Walzer,3 Bülent Akmaz2 1Karl Landsteiner Society, Center for Public Health, Medical University of Vienna, Vienna, Austria; 2Global Market Access, Pricing and Medical Affairs, Almirall S.A., Barcelona, Spain; 3Health Economics and Market Access, MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, GermanyCorrespondence: Yannick Walzer, Health Economics and Market Access, MArS Market Access and Pricing Strategy GmbH, Geffelbachstraße 6, Weil am Rhein, Baden-Württemberg, 79576, Germany, Email yannick.walzer@marketaccess-pricingstrategy.deIntroduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant economic burden. This study evaluated the cost-effectiveness of lebrikizumab compared to dupilumab for adults and adolescents with severe AD from an Austrian healthcare payer’s perspective.Methods: A cost-effectiveness analysis, based on the NICE assessment’s TA986 model, was conducted, comprising a decision tree for the first year and a Markov model for long-term outcomes. The analysis adopted a healthcare system perspective, discount rate (3%) and applied Austrian-specific data, costs and quality of life measures. Two scenarios assessed the robustness of the base case analysis.Results: The base case analysis showed lebrikizumab was associated with lower total costs (€ 128,961 vs € 133,870) and slightly lower QALYs (16.53 vs 16.56) compared to dupilumab over a lifetime horizon. The primary driver of cost savings was lower drug acquisition costs for lebrikizumab (-€ 5,349). Scenario analyses with different economic and clinical data demonstrated cost-effectiveness for lebrikizumab.Discussion: This economic evaluation suggests lebrikizumab is a potential cost-saving alternative to dupilumab based on the base case analysis of this health economic model for severe AD treatment in Austria, with comparable clinical efficacy. Consequently, lebrikizumab has been reimbursed in Austria since January 2025 as the second biological therapeutic option alongside dupilumab, following national pricing and reimbursement rules.Keywords: atopic dermatitis, biologics, Cost-effectiveness-analysis (CEA), dupilumab, lebrikizumab
Orrin I Franko,1 James M Saucedo,2 Richard B Schaefer,3 Larry E Miller,4 Brian C Najarian5 1East Bay Hand Medical Center, San Leandro, CA, USA; 2UT Health Houston, Houston, TX, USA; 3SSM Health Fond du Lac Regional Clinic, Fond du Lac, WI, USA; 4Department of Biostatistics, Miller Scientific, Johnson City, TN, USA; 5Cape Cod Orthopaedics, Hyannis, MA, USACorrespondence: Larry E Miller, Department of Biostatistics, Miller Scientific, Johnson City, TN, USA, Email larry@millerscientific.comObjective: Ultrasound-guided carpal tunnel release (UGCTR) is an office-based alternative to open (OCTR) and endoscopic carpal tunnel release (ECTR), which are typically performed in ambulatory surgical centers or hospital outpatient departments. The economic implications of transitioning surgical volume to an office-based UGCTR pathway from a commercial payer perspective have not been evaluated. This study estimated the per-episode cost differences and annual budget impact of adopting office-based UGCTR compared with conventional OCTR and ECTR from a US commercial payer perspective.Methods: A decision-analytic cost comparison model was developed using the 2020 IBM MarketScan Commercial Claims and Encounters database. Episode costs included preoperative evaluation (physician visit, diagnostic ultrasound, electrodiagnostic testing), procedural costs (physician fees, facility fees, anesthesia), and postoperative rehabilitation. UGCTR costs were modeled at 150% of the Centers for Medicare and Medicaid Services rate for the anticipated CPT code. One-way deterministic sensitivity analyses were performed for all varying parameters. A probabilistic sensitivity analysis using Monte Carlo simulations assessed model robustness.Results: Total per-episode costs were $3646 for the blended standard of care (75% OCTR / 25% ECTR) and $2598 for UGCTR. UGCTR was associated with per-episode savings of $1048 (28.7%), primarily driven by elimination of facility fees and anesthesia charges, which accounted for 86.8% of total savings. For a hypothetical 2-million-member commercial health plan, annual savings were $2,096,000 at 50% conversion to office-based UGCTR (per-member-per-month savings: $0.09). The UGCTR physician fee and standard of care facility fees were the dominant drivers of model uncertainty. Office-based UGCTR was cost-saving in 100% of the simulations (mean savings: $1123; 95% credible interval: $620-$1664).Conclusion: Office-based UGCTR was associated with lower per-episode costs compared with facility-based OCTR and ECTR, driven primarily by elimination of facility fees and anesthesia charges. These findings support the economic rationale for commercial payer coverage of office-based UGCTR.Keywords: budget impact analysis, carpal tunnel release, carpal tunnel syndrome, commercial claims, office, site of service, ultrasound
Chiara Bini,1 Andrea Marcellusi,1 Barbara Muzii,2 Samira Soudani,3 Sara Trotta,2 Salvatore Parisi,2 Elena Bozzola,4 Paolo Bonanni,5 Sara Boccalini51Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment (CEIS-EEHTA), Faculty of Economics, University of Rome ‘Tor Vergata’, Rome, 00133, Italy; 2Sanofi, Rome, Italy; 3Sanofi, Lyon, France; 4IRCCS Bambino Gesù Children Hospital, Rome, Italy; 5Department of Health Sciences, University of Florence, Florence, 50134, ItalyCorrespondence: Chiara Bini, Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata”, Rome, 00133, Italy, Tel +393287236584, Email chiara.bini@uniroma2.itObjective: This study aimed to estimate the potential clinical and economic impact of nirsevimab and of a maternal vaccine in the prevention of medically attended (MA) RSV-associated lower respiratory tract infections (LRTIs) in the entire cohort of newborns entering their first RSV season in Italy compared with the absence of prevention strategies.Methods: A cost-consequence analysis using a static decision tree model previously published was conducted to estimate the RSV-MA-LRTIs and associated mid-long-term complications avoided with each immunization strategy during a single RSV epidemic season. Nirsevimab efficacy was derived from the pooled analysis of Phase 3 MELODY and Phase 2b clinical trials and a protection of 6 months with constant efficacy was considered. For maternal immunization (MI), the efficacy for term infants was derived from MATISSE clinical trial and it was considered until 6 months of age. Zero efficacy was assumed starting from the seventh month for both preventive strategies. The time horizon of the analysis corresponding to one RSV epidemic season. National Health Service (NHS) perspective was considered in the base-case.Results: From the NHS perspective, over the first RSV season, the immunization strategy with MI compared with no preventive strategies could lead to a reduction of 68,358 RSV-MA-LRTIs and 6,417 associated mid-long-term complications. These reductions in terms of RSV‑related health events can be translated into economic savings of about € 24.5 million. The immunization strategy with nirsevimab compared with no preventive strategies could lead to a reduction of 118,123 RSV-MA-LRTIs, 8,480 associated mid-long-term complications. The economic saving associated with these reductions in terms of RSV-related health events was estimated equal to € 34.2 million.Conclusion: Both preventive strategies represent effective measures for the prevention of RSV infections in infants. The organizational impact of these two strategies should also be assessed, in addition to ensuring appropriate counselling for pregnant women and the parents of infants, to avoid missing these immunization opportunities against RSV. These findings may support public health decision-making and inform future policy strategies.Keywords: respiratory syncytial virus, universal immunization, economic evaluation, prophylactic strategies
Mehul Desai,1 Navin Goyal,2 Brian Penick,2 James T Kenney,3 Edmund J Pezalla,4 Marshall A Kuremsky21Enable Injections Inc., Cincinnati, OH, USA; 2Beyond Physician, Inc., Columbus, OH, USA; 3JTKenney LLC, Waltham, MA, USA; 4Enlightenment Bioconsult, Wethersfield, CT, USACorrespondence: Mehul Desai, Enable Injections Inc., Cincinnati, OH, USA, Email mdesai@enableinjections.comObjective: Desai et al (2024) reported that 88.2% of 17 surveyed US payers would consider covering and managing drugs packaged with a novel large-volume on-body delivery system (OBDS) but not how individual payers would operationalize that coverage. This follow-on study used patent-pending, per-respondent voice-intelligence analysis to identify those mechanisms.Methods: Recordings of 11 of the 17 Desai 2024 interviews (93.7 million of the original 227 million covered lives) were analyzed using VOICE (Beyond Physician), a commercial voice-intelligence platform that scored six payer dimensions per respondent as a fixed-weight composite of transcript sentiment (60%), acoustic emotion (25%), and direct acoustic features (15%). Findings were reconciled with Desai 2024.Results: Three cross-file findings replicated: (1) a drug-centric coverage framework (5 of 11, plus 2 partially) helps explain why high feature ratings in Desai 2024 were not decisive for coverage; (2) 10 of 11 payers indicated that patient preference data alone is insufficient for coverage decisions without paired outcomes correlation; and (3) site-of-care enforcement was identified through five distinct mechanisms in five of six regional managed care organizations. Reconciliation found all eight directly comparable Desai 2024 findings consistent with the subset, with dissenting respondents reported where present.Conclusion: Voice-intelligence re-analysis of the same recordings was consistent with all directly comparable Desai 2024 findings and added per-respondent operational depth. Per-respondent analysis identified operational mechanisms, such as five site-of-care enforcement approaches, that the aggregate analysis did not report. The approach is applicable to other recorded qualitative stakeholder interview datasets where per-respondent reasoning adds value.Keywords: payer, on-body delivery system, subcutaneous, voice intelligence, on-body injector, artificial intelligence, AI voice analysis